Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06229665 · ClinicalTrials.gov registry record · Phase 2
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
A Phase 2 study of Dry Age-Related Macular Degeneration, sponsored by LumiThera.
- Active
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 7
- Study locations
NCT06229665 is a Phase 2 study of Dry Age-Related Macular Degeneration that is active but no longer recruiting, run by LumiThera. The registered enrollment target is 75 participants, roughly in line with the 73-participant average among 7 other Dry Age-Related Macular Degeneration trials with a reported enrollment target. The trial reports 7 study locations across 6 states.
The verdict
NCT06229665, a Phase 2 study of Dry Age-Related Macular Degeneration, is active but no longer recruiting, sponsored by LumiThera.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is an open-label, prospective, multi-center extension study on the continued use of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) that participated in the CSP005 LIGHTSITE III study.
Conditions Studied
Interventions
- DEVICE Valeda Light Delivery System
Study Locations (7)
California
- Retina Vitreous Associates Medical Group - Beverly Hills
- Stanford University - Palo Alto
Florida
- Florida Eye Clinic - Altamonte Springs
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
New York
- New York Ear and Eye Infirmary - New York
Texas
- Gulf Coast Eye Institute - McAllen
Washington
- Retina Center Northwest - Silverdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2025-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06229665
The ClinicalTrials.gov registry entry for NCT06229665 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 73-participant average among 7 other Dry Age-Related Macular Degeneration trials with a reported enrollment target. The listed sponsor is LumiThera, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Age-Related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Valeda Light Delivery System is the first listed.
NCT06229665 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06229665 about?
NCT06229665 is a clinical study titled "Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)". This study is an open-label, prospective, multi-center extension study on the continued use of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) that participated in the CSP005 LIGHTSITE III study.
What is the current status of trial NCT06229665?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2023-10-25. Estimated completion is 2025-06-01.
What conditions does trial NCT06229665 study?
This clinical trial studies the following conditions: Dry Age-Related Macular Degeneration.
What interventions are being tested in trial NCT06229665?
The interventions under investigation include: Valeda Light Delivery System (DEVICE).
Who is sponsoring clinical trial NCT06229665?
This trial is sponsored by LumiThera, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06229665 being conducted?
This trial has 7 study locations across California, Florida, Maryland, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Age-Related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RECRUITING · Phase 1
-
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
PRIMA US-Feasibility Study in Atrophic Dry AMD
ACTIVE NOT RECRUITING · NA
-
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
ACTIVE NOT RECRUITING
-
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.